Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity ...

A combination featuring Exelixis’ experimental drug zanzalintinib has beaten Bayer’s gastrointestinal cancer med Stivarga in ...

Aiming T-cell engagers at autoimmune diseases continues to be a red-hot deal-making target, as evidenced by Otsuka ...

Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

The FDA has stopped new clinical trials that export American citizens’ living cells from the U.S. to “China and other hostile ...

Multiple developers of connected diabetes hardware have announced plans this week to link their insulin pumps with continuous ...

The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...

BMS didn’t want to choose between clinical expertise and financial know-how when selecting a new strategy leader. The Big ...

Biotech has always been a little unconventional, but, as the industry’s bear market drags on, efforts to stay afloat are ...

Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to ...

The miniaturized surgical robot maker Virtual Incision has pinched a new CEO, as it aims to expand its commercial reach ...